Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15536106 | 0.92 | KDM2B (0.38) | HCAR3HSD17B10GAASRD5A2EPHX2 | |
| SCHEMBL24036216 | 0.83 | KDM2B (0.54) | L3MBTL1KDM2BALDH1A1KMT2AL3MBTL3 | |
| SCHEMBL24035853 | 0.80 | TSHR (0.33) | SRD5A2KMOKDM2BALDH1A1POLB | |
| SCHEMBL29064949 | 0.80 | TSHR (0.33) | GAASRD5A2KDM2BALDH1A1 | |
| SCHEMBL24035870 | 0.80 | ALDH1A1 (0.48) | HSD17B10GAAEPHX2KDM4EALDH1A1 | |
| SCHEMBL24035829 | 0.78 | HCAR3 (0.33) | HCAR3KDM2B | |
| SCHEMBL24035863 | 0.78 | KDM4C (0.34) | KMOKDM2B | |
| SCHEMBL24036219 | 0.77 | KDM2B (0.46) | L3MBTL1KDM2BALDH1A1KMT2AL3MBTL3 | |
| SCHEMBL29064966 | 0.76 | HCAR3 (0.33) | HCAR3SRD5A2KMO | |
| SCHEMBL28966557 | 0.76 | HCAR3 (0.33) | HCAR3HSD17B10GAASRD5A2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | HCAR3 3585/4885HSD17B10 3076/4885GAA 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.